Safety and efficacy of retromuscular-onlay dual-mesh reconstruction for massive abdominal wall defects secondary to abdominal wall endometriosis resection - Takeaways - MDSpire

Safety and efficacy of retromuscular-onlay dual-mesh reconstruction for massive abdominal wall defects secondary to abdominal wall endometriosis resection

  • By

  • Dongbing Ding

  • Yuan Wang

  • Han Wang

  • Rongpu Liang

  • Jiarong You

  • Qingjian Ye

  • Bo Wei

  • May 13, 2026

  • 0 min

Share

  • 1

    Abdominal wall endometriosis (AWE) is rare, often requiring radical excision that can lead to significant abdominal wall defects.

  • 2

    The retromuscular-onlay dual-mesh technique disperses intra-abdominal pressure and provides anterior support, enhancing abdominal wall stability.

  • 3

    A retrospective study of nine women showed that the dual-mesh approach resulted in no significant postoperative complications.

  • 4

    The average surgery duration was 114 minutes, with minimal blood loss and an average hospital stay of 8.5 days.

  • 5

    The study indicates that the dual-mesh technique is a safe option for reconstructing abdominal wall defects after AWE resection.

Original Source(s)

Safety and efficacy of retromuscular-onlay dual-mesh reconstruction for massive abdominal wall defects secondary to abdominal wall endometriosis resection

  • by Dongbing Ding, Yuan Wang, Han Wang, Rongpu Liang, Jiarong You, Qingjian Ye, Bo Wei

  • May 13, 2026

Related Content

Transumbilical laparoscopic-assisted appendectomy: a feasible minimally invasive option for pediatric acute appendicitis with comparable outcomes to three-port laparoscopic appendectomy

Comparative study on the clinical efficacy of laparoscopic cervicoisthmic cerclage and transvaginal cervical cerclage in the treatment of cervical insufficiency after hysteroscopic adhesiolysis for intrauterine adhesions: a retrospective cohort study

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.